相关实验视频
Updated: Jan 16, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.4K
鼻癌免疫治疗的预测生物标志物:从瘤微环境到宏观环境
Saiwei Huang1, Yelin Liang1, Na Liu2
1Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Frontiers of medicine
|September 28, 2025
概括
确定可靠的生物标志物对于预测哪些鼻癌患者可以从免疫治疗中受益至关重要. 本综述探讨了鼻癌免疫疗法预测生物标志物研究当前的进展和挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 生物标志物研究 生物标志物研究
背景情况:
- 免疫疗法,包括PD-1阻断,结合化疗和放射疗法,对鼻癌 (NPC) 有希望.
- 然而,只有少数患者对抗PD-1疗法有反应,这凸显了对预测生物标志物的需求.
- 识别这些生物标志物对于优化治疗策略至关重要.
研究的目的:
- 审查NPC免疫疗法的最新进展.
- 总结NPC患者免疫治疗反应和生存的潜在预测生物标志物.
- 讨论临床应用生物标志物开发的挑战和未来方向.
主要方法:
- 关于NPC免疫疗法的最新进展的文献综述.
- 对瘤微环境和宏观环境中生物标志物识别研究的分析.
- 在随机对照试验中对生物标志物验证的评估.
主要成果:
- 瘤微环境和宏环境中的几种生物标志物与免疫疗法反应或生存有相关性.
- 一些生物标志物已在随机对照试验中得到验证,而另一些则需要进一步调查.
- 目前的研究确定了潜在的预测因素,但强调需要强有力的验证.
结论:
- 预测性生物标志物对于选择NPC患者从免疫疗法中获益至关重要.
- 在临床实施之前,需要对已识别的生物标志物进行进一步验证.
- 对预测生物标志物的持续研究将促进NPC的个性化免疫疗法.
相关概念视频
02:17The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K